Treating autoimmune disorders is an escalating medical and social challenge in our community. As about 1% of the world's population is afflicted by rheumatoid arthritis (RA), there is an urgent need for better therapies which originate from conducting relevant experiments in the laboratory before translating into clinical trials. Currently, there is no known cure for RA. However, early medical intervention has been shown to be important in improving outcomes with drugs such as anti-TNFs. As T cells are thought to play an important role in the initiation of RA, we hypothesized that early targeting of both TNF and T cells would result in better outcomes. The aim of this thesis was to examine the efficacy of combining anti-CD3 and anti-TNF therapies in experimental RA. Taken together, the results demonstrate a synergy when combining these treatments, providing a longer term relief from inflammation and disease progression than of either monotherapy.